Bristol-Myers Squibb BMY Opdivo — Total Revenues

Other product segments

Similar metrics at other companies

NWETotal Revenue — Total Revenues

$497.57M+6.6%

ACNConsulting Revenue — Total Revenues

$9.33B+3.6%

CMEOther Revenue — Total Revenues

$115.6M+9.2%

AEPOther Revenues — Total Revenues

$158M+19.7%

AEPTransmission Revenues — Total Revenues

$110M+3.8%

CUZOther — Total Revenues

$756K-88.9%

FAQ

What is Bristol-Myers Squibb's opdivo — total revenues?

Bristol-Myers Squibb (BMY) reported opdivo — total revenues of $2.49B in Q2 2026.

How has Bristol-Myers Squibb's opdivo — total revenues changed year-over-year?

Bristol-Myers Squibb's opdivo — total revenues decreased by 2.9% year-over-year, from $2.56B to $2.49B.

What is the long-term trend for Bristol-Myers Squibb's opdivo — total revenues?

Over 4 years (2021 to 2025), Bristol-Myers Squibb's opdivo — total revenues has grown at a 7.5% compound annual growth rate (CAGR), from $7.52B to $10.05B.

What does opdivo — total revenues mean?

This metric represents the total global net sales generated from the commercialization of the PD-1 inhibitor therapy Opdivo. As a cornerstone of the company's immuno-oncology portfolio, these revenues reflect the drug's market penetration, clinical adoption rates, and competitive positioning against other checkpoint inhibitors. It serves as a primary indicator of the company's success in the oncology therapeutic area.